Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Argenx Se ADR
(NQ:
ARGX
)
434.22
+4.18 (+0.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
349,403
Open
430.45
Bid (Size)
423.44 (1)
Ask (Size)
444.04 (1)
Prev. Close
430.04
Today's Range
428.97 - 438.12
52wk Range
327.73 - 550.76
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
June 25, 2024
From
argenx SE
Via
GlobeNewswire
Why Is European Drugmaker Argenx Stock Trading Higher On Monday?
June 24, 2024
The FDA has approved Argenx's Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy, with projections of $1.2 billion in U.S. revenues by 2030.
Via
Benzinga
Exposures
Product Safety
Performance
YTD
+13.97%
+13.97%
1 Month
+17.03%
+17.03%
3 Month
+9.28%
+9.28%
6 Month
+13.97%
+13.97%
1 Year
+13.80%
+13.80%
More News
Read More
Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
June 24, 2024
Via
Investor's Business Daily
Exposures
Product Safety
Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday
June 24, 2024
Via
Benzinga
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
June 24, 2024
Via
Benzinga
Breaking Down argenx: 12 Analysts Share Their Views
May 10, 2024
Via
Benzinga
The Analyst Verdict: argenx In The Eyes Of 12 Experts
April 18, 2024
Via
Benzinga
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
June 21, 2024
From
argenx SE
Via
GlobeNewswire
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
June 17, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
argenx SE
Via
GlobeNewswire
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
May 30, 2024
Via
Investor's Business Daily
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
May 29, 2024
Via
Benzinga
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
May 29, 2024
Via
Investor's Business Daily
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
May 09, 2024
Via
Benzinga
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
May 09, 2024
Via
Benzinga
ARGX Stock Earnings: argenx Misses EPS, Misses Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
May 09, 2024
Via
Benzinga
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
argenx SE
Via
GlobeNewswire
argenx announces results of Annual General Meeting of Shareholders
May 07, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Present at BofA Securities 2024 Health Care Conference
May 07, 2024
From
argenx SE
Via
GlobeNewswire
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
May 02, 2024
From
argenx SE
Via
GlobeNewswire
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
April 16, 2024
From
argenx SE
Via
GlobeNewswire
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
April 10, 2024
Via
Benzinga
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
March 27, 2024
From
argenx SE
Via
GlobeNewswire
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
March 26, 2024
From
argenx SE
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.